Apr. 10 at 10:01 PM
I’m watching
$MTVA. Traders have reached positively to the continuation of a trial on an obesity drug, with
$MTVA rising 18.49% to 1.41 in the Regular Session.
MetaVia looks to be starting a good “First Step” towards a larger move, quite likely after a test of its 20 Day SMA support at 1.34 in the coming days. Upside targets are the 200 Day SMA at 6.67 offering a potential 373% gain, with analysts’ price targets as high as 20 with a potential 1,318% gain.
But wait for the retest of the 20 Day SMA over the coming week.
$MTVA has a history of retesting SMA support levels before making big moves up, unless it is filling down gaps, which is not the case here.
